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MaBACKGROUND Patients with heart failure (HF) are at high risk for hospital readmission in the ﬁrst 30 days following HF
hospitalization.
OBJECTIVES This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital
readmission at 30-days following HF hospitalization compared with enalapril.
METHODS We assessed the risk of 30-day readmission for any cause following investigator-reported hospitalizations
for HF in the PARADIGM-HF trial, which randomized 8,399 participants with HF and reduced ejection fraction to treat-
ment with LCZ696 or enalapril.
RESULTS Accounting for multiple hospitalizations per patient, there were 2,383 investigator-reported HF hospitaliza-
tions, of which 1,076 (45.2%) occurred in subjects assigned to LCZ696 and 1,307 (54.8%) occurred in subjects assigned
to enalapril. Rates of readmission for any cause at 30 days were 17.8% in LCZ696-assigned subjects and 21.0% in
enalapril-assigned subjects (odds ratio: 0.74; 95% conﬁdence interval: 0.56 to 0.97; p ¼ 0.031). Rates of readmission for
HF at 30-days were also lower in subjects assigned to LCZ696 (9.7% vs. 13.4%; odds ratio: 0.62; 95% conﬁdence in-
terval: 0.45 to 0.87; p ¼ 0.006). The reduction in both all-cause and HF readmissions with LCZ696 was maintained when
the time window from discharge was extended to 60 days and in sensitivity analyses restricted to adjudicated HF
hospitalizations.
CONCLUSIONS Compared with enalapril, treatment with LCZ696 reduces 30-day readmissions for any cause following
discharge fromHF hospitalization. (J AmColl Cardiol 2016;68:241–8)© 2016 by the American College of Cardiology Foundation.D espite considerable progress in the devel-opment of effective medical therapy, pa-tients with heart failure (HF) remain at
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AB BR E V I A T I O N S
AND ACRONYM S
CEC = Clinical Endpoints
Committee
CI = conﬁdence interval
HF = heart failure
LCZ696 = sacubitril/valsartan
OR = odds ratio
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243Global Mortality and Morbidity in Heart Failure) trial,
treatment with the angiotensin receptor neprilysin
inhibitor sacubitril/valsartan (LCZ696) was associ-
ated with a 20% reduction in the primary composite
endpoint of cardiovascular death or HF hospitaliza-
tion compared with enalapril (6). Moreover, LCZ696
reduced both the time to ﬁrst hospitalization for HF
and the cumulative burden of HF hospitalizations
during the course of the trial (7). In this analysis, we
sought to further assess the effect of LCZ696 on the
rates of all-cause 30-day readmission after HF
hospitalization.TABLE 1 Baseline Characteristics of Patients With Discharge After
Investigator-Reported Heart Failure Hospitalization, by Treatment Assignment
Hospitalized for HF
p Value
(Enalapril vs. LCZ)
LCZ696
(n ¼ 675)
Enalapril
(n ¼ 775)
Age, yrs 64.4  11.7 64.3  11.4 0.82
Female 17 19 0.29
White race 69 67 0.50
BMI, kg/m2 28.5  5.8 28.7  5.8 0.45
SBP, mm Hg 121  16 121  16 0.74
Heart rate, bpm 74  12 74  13 0.91
Creatinine, mg/dl 1.2  0.3 1.2  0.3 0.66
Ischemic CMP 60 60 0.91
Ejection fraction, % 29  6 29  7 0.92
Median NT-proBNP, pg/ml 2,270 (1,178–4,749) 2,000 (1,079–4,587) 0.10
NYHA class 0.16
I 3 4
II 65 69
III 30 26
IV 2 1
Past medical history
Hypertension 74 75 0.83
Diabetes 44 43 0.81
Hospitalization for HF 74 74 0.95
MI 48 45 0.29
Stroke 11 11 0.96
Atrial ﬁbrillation 39 45 0.015
Treatment at randomization
Diuretics 87 87 0.70
Digitalis 31 35 0.08
Beta-blocker 92 93 0.79
MRA 57 56 0.68
ICD 21 20 0.92
CRT 10 9 0.44
Values are mean  SD, %, or median (interquartile range).
BMI ¼ body mass index; CMP ¼ cardiomyopathy; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure;
ICD ¼ implantable cardioverter-deﬁbrillator; LCZ696 ¼ sacubitril/valsartan; MI ¼ myocardial infarction; MRA ¼
mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New
York Heart Association; SBP ¼ systolic blood pressure.
SEE PAGE 249METHODS
PARADIGM-HF TRIAL. As previously reported (8),
the PARADIGM-HF study was a randomized, double-
blind, prospective comparison of LCZ696 with ena-
lapril in subjects with chronic HF, New York Heart
Association functional class II to IV symptoms, and
left ventricular ejection fraction of #40% (subse-
quently lowered to #35% by an amendment to
the protocol) treated with guideline-recommended
medical therapy. Before randomization, all subjects
underwent a sequential, single-blind run-in phase
to ensure tolerability of both study drugs at target
doses. Subjects who successfully completed the
run-in phase (n ¼ 8,399) were randomly allocated in
1:1 fashion to double-blind treatment with either
enalapril, 10 mg twice daily or LCZ696, 200 mg
twice-daily (sacubitril/valsartan, 97/103 mg twice-
daily). Ethics committee approval was obtained
for the study at each site, and written informed
consent was obtained from all subjects before
participation.
STATISTICAL ANALYSES. Baseline characteristics of
patients who were hospitalized and subsequently
discharged were analyzed by treatment arm, using
Student t tests and Pearson chi-squared test for
continuous and categorical data, respectively. To
incorporate data from multiple HF hospitalizations
per patient, the primary unit of subsequent analysis
was hospitalizations, rather than patients. We
compared rates of 30-day readmission after index HF
hospitalization by treatment assignment during the
median 27-month period of randomized follow-up in
the PARADIGM-HF trial. To replicate the approach
used in the Hospital Readmissions Reduction Pro-
gram, all investigator-reported hospitalizations for
HF were considered as potential index HF hospitali-
zations, not merely those that were adjudicated
positively by the Clinical Endpoints Committee (CEC).Those in which patients died before
discharge, were admitted and discharged on
the same day, or for which discharge dates
were unavailable were excluded. Discharges
for which readmission status was not able to
be determined because of study discontinu-
ation were omitted from the analysis. When
conﬂicting admission and/or discharge dates
were encountered, we used the widest hos-
pitalization interval from among the conﬂicting dates
(i.e., the earliest admission date and the latest
discharge date). In keeping with the Medicare meth-
odology, a readmission was deﬁned as inpatient
admission to an acute care facility for any cause
within 30-days from the date of discharge of an index
HF hospitalization.
FIGURE 1 Summary of Patient Flow for the Analysis
8399 Randomized Patients
4187 Randomized
to LCZ696
4212 Randomized
to Enalapril
770 (18%) with investigator-reported HF
hospitalization
•
•
•
•
•
•
•
•
•
•
•
•
•
•
675 patients with ≥1 valid discharge 775 patients with ≥1 valid discharge
1076 total discharges 1307 total discharges
4 did not have complete date information
15 were discharged prior to randomization
76 died during 1st HF hospitalization
884 (21%) with investigator-reported HF
hospitalization
12 did not have complete date information
15 were discharged prior to randomization
82 died during 1st HF hospitalization
9 with undetermined readmission status
92 with 30-day readmission after first discharge
126 with 30-day readmission at any time
192 with 30-day readmission
15 with undetermined readmission status
125 with 30-day readmission after first discharge
195 with 30-day readmission at any time
275 with 30-day readmission
The diagram summarizes for each treatment arm the number of patients with an investigator-reported HF hospitalization, the subset with at
least 1 valid discharge following an investigator-reported HF hospitalization, the total number of HF discharges considered as index admissions
for the readmissions analysis, and the number of 30-day readmissions in each group. HF ¼ heart failure; LCZ696 ¼ sacubitril/valsartan.
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versus enalapril-treated patients were calculated in
random-effects logistic regression models to account
for multiple HF discharge windows experienced by
the same patient. Sensitivity analyses were conduct-
ed examining only patients >65 years of age, exam-
ining all-cause readmissions at 60 days, examining
only cause-speciﬁc readmission for HF, restricting the
analysis to patients enrolled in the United States
(where ﬁnancial penalties for 30-day readmissions
after HF hospitalization are most applicable), and
using only the subset of investigator-reported HF
hospitalizations conﬁrmed by the CEC. Sensitivity
analyses restricted to the ﬁrst HF discharge for each
patient used standard logistic regression models.
RESULTS
Of 8,399 randomized subjects, 1,654 (19.7%) experi-
enced an investigator-reported HF hospitalization.
Excluding those hospitalizations for which complete
date information was unavailable, or the patient died
while hospitalized, there were 1,450 (17.3%) subjects
who survived at least 1 HF hospitalization including675 (16.1%) assigned to LCZ696 and 775 (18.4%)
assigned to enalapril. Among patients hospitalized at
least once for HF, patient characteristics were similar
at baseline between treatment groups (Table 1).
Accounting for multiple hospitalizations per pa-
tient, there were 2,383 investigator-reported HF
hospitalizations, of which 1,076 (45.2%) occurred in
subjects assigned to LCZ696 and 1,307 (54.8%)
occurred in subjects assigned to enalapril (Figure 1).
Length of stay during index HF hospitalization did
not differ by treatment arm (7.5 days vs. 7.0 days,
sacubitril/valsartan vs. enalapril; p ¼ 0.10). The
number of readmissions per patient is summarized in
Online Figure 1 and Online Table 1. Rates of read-
mission for any cause at 30 days were 17.8% in
LCZ696-assigned subjects and 21.0% in enalapril-
assigned subjects (OR: 0.74; 95% conﬁdence interval
[CI]: 0.56 to 0.97; p ¼ 0.031). Rates of readmission for
HF at 30 days were also reduced in subjects assigned
to LCZ696 (9.7% vs. 13.4%; OR: 0.62; 95% CI: 0.45 to
0.87; p ¼ 0.006). The reduction in both all-cause and
HF readmissions with LCZ696 was maintained when
the time window from discharge was extended to 60
days (all-cause readmissions: 27.8% vs. 30.5%; OR:
CENTRAL ILLUSTRATION Inﬂuence of LCZ696 on Readmission: Rates After Investigator-Reported
HF Hospitalization According to Treatment Assignment
Desai, A.S. et al. J Am Coll Cardiol. 2016;68(3):241–8.
Shown are the proportion of investigator-reported HF hospitalizations associated with readmissions for any cause or for heart failure at 30 days and 60 days following
discharge. LCZ696 ¼ sacubitril/valsartan.
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2450.77; 95% CI: 0.60 to 0.99; p ¼ 0.045) (HF read-
missions: 17.1% vs. 20.3%; OR: 0.68; 95% CI: 0.50 to
0.92; p ¼ 0.01) (Central Illustration, Figure 2).
The results of sensitivity analyses are reported in
Figure 2. Among analyses restricted to CEC-
adjudicated HF hospitalizations, 30-day all-cause
readmission rates were similarly lower in subjects
assigned to LCZ696 (17.7% vs. 20.7%; OR: 0.74; 95%
CI: 0.55 to 0.99; p ¼ 0.043). Numerically fewer all-
cause and HF-related readmissions at 30 days were
also noted for LCZ696-assigned subjects 65 years and
older (Medicare-eligible, 17.8% vs. 20.7%; OR: 0.82;
95% CI: 0.57 to 1.19; p ¼ 0.30) and those enrolled in
the United States (17.3% vs. 26.0%; OR: 0.60; 95% CI:
0.29 to 1.26; p ¼ 0.18), with more pronounced effecton HF readmissions in each of these subgroups. The
effect of LCZ696 on all-cause and HF readmissions did
not differ signiﬁcantly across regions pre-speciﬁed
in the primary analysis (p ¼ 0.81 for all-cause and
p ¼ 0.09 for HF readmissions) (Online Figure 2).
DISCUSSION
Among patients with HF and reduced ejection frac-
tion enrolled in the PARADIGM-HF trial, treatment
with LCZ696 reduced the cumulative incidence of HF
hospitalizations relative to treatment with enalapril.
Nearly 1 in 5 HF hospitalizations during the trial was
followed by a repeat hospitalization within 30 days,
of which more than half were related to recurrent HF.
FIGURE 2 Sensitivity Analyses of Impact of LCZ696 Relative to Enalapril on Readmission Rates After HF Hospitalization
0.2 0.4 0.6 0.8 1.0 1.2 1.4
Odds Ratio (95% CI)
Analysis LCZ696 Enalapril Odds Ratio P-Value
30-day (after any investigator-reported HF Hosp)
30-day (after first investigator-reported HF Hosp)
30-day (after any CEC-confirmed HF Hosp)
60-day (after any investigator-reported HF Hosp)
30-day (after any investigator-reported HF Hosp):
Subgroup: Patients at least 65 years
Subgroup: Patients less than 65 years
Subgroup: US Patients
Subgroup: non-US Patients
All-cause readmission
HF readmission
All-cause readmission
HF readmission
All-cause readmission
HF readmission
All-cause readmission
HF readmission
All-cause readmission
HF readmission
All-cause readmission
HF readmission
192/1076 (17.8%)
104/1074 (9.7%)
275/1307 (21.0%)
175/1302 (13.4%)
0.74 (0.56-0.97)
0.62 (0.45-0.87)
0.031
0.006
294/1059 (27.8%)
180/1055 (17.1%)
391/1283 (30.5%)
259/1275 (20.3%)
0.77 (0.60-0.99)
0.68 (0.50-0.92)
0.045
0.013
All-cause readmission
All-cause readmission
92/666 (13.8%) 125/760 (16.4%) 0.81 (0.61-1.09) 0.17
171/967 (17.7%) 243/1172 (20.7%) 0.74 (0.55-0.99) 0.043
101/567 (17.8%)
47/565 (8.3%)
133/644 (20.7%)
94/643 (14.6%)
0.82 (0.57-1.19)
0.47 (0.28-0.77)
0.30
0.003
91/509 (17.9%)
57/509 (11.2%)
142/663 (21.4%)
81/659 (12.3%)
0.65 (0.43-0.98)
0.83 (0.53-1.31)
0.041
0.42
18/104 (17.3%)
6/104 (5.8%)
34/131 (26.0%)
21/131 (16.0%)
0.60 (0.29-1.26)
0.36 (0.12-1.09)
0.18
0.07
174/972 (17.9%)
98/970 (10.1%)
241/1176 (20.5%)
154/1171 (13.2%)
0.75 (0.56-1.01)
0.65 (0.46-0.93)
0.06
0.018
Shown are the proportion of readmissions for any cause or for HF, by treatment arm, along with odds ratios for readmission (LCZ696 vs. enalapril) and 95% CIs, for
varying deﬁnitions of index HF events (investigator-reported vs. CEC-conﬁrmed), varying time horizons (30 vs. 60 days), and key subgroups of interest. CEC ¼ Clinical
Endpoints Committee; CI ¼ conﬁdence interval; Hosp ¼ hospitalization; other abbreviations as in Figure 1.
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246In this analysis, we noted a 26% lower rate of 30-day
readmission for any cause among patients allocated
to LCZ696 and a 38% lower rate of 30-day read-
mission for HF. These differences persisted at 60 days
following hospital discharge and were robust in ana-
lyses restricted to CEC-adjudicated HF hospitaliza-
tions, patients enrolled in the United States, and the
subset of Medicare-eligible subjects >65 years of age.
These data suggest that LCZ696 is likely to be more
effective than enalapril in reducing the risk of early
readmission after HF hospitalization.
Recurrent hospitalizations are a primary driver of
the burgeoning costs associated with HF care (3) and
are a potent marker of risk for subsequent mortality
(9,10). Although patients discharged with HF are at
risk for readmission well beyond 30 days, the early
post-discharge interval is known to be a particularly
vulnerable period (11,12). In the United States,ﬁnancial penalties imposed as part of the Hospital
Readmission Reduction Program have focused
considerable attention on improving the quality of
pre-discharge education, care transitions, and
early post-discharge follow-up to reduce the burden
of preventable admissions (13). However, few
evidence-based strategies for readmission prevention
are available. Guidelines encourage prescription of
neurohormonal antagonists before hospital discharge
to improve adherence and long-term clinical out-
comes in patients with HF and reduced ejection frac-
tion (14), but there are limited data assessing the
impact of existing guideline-directed medical thera-
pies on the risk of readmissions in the 30- or 60-day
window following discharge. A recent observational
study of digoxin prescription before discharge sug-
gested a signiﬁcant reduction on 30-day readmissions
among patients with HF and ejection fraction <45%
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Thirty-day readmission is common among patients
hospitalized with heart failure and rates are lower in those
treated with sacubitril/valsartan than in patients treated with
enalapril.
TRANSLATIONAL OUTLOOK: Future studies should seek to
clarify the mechanism by which composite angiotensin receptor-
neprilysin inhibition exerts beneﬁt beyond the acute hospital
phase of treatment compared with angiotensin-converting
enzyme inhibition alone in patients with progressive heart failure
and reduced ejection fraction.
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247(15), but studies examining pre-discharge prescription
of angiotensin-converting enzyme inhibitors (16),
beta-blockers, (17) and ﬁxed-dose isosorbide dinitrate/
hydralazine (18) have not shown similar beneﬁts,
despite important effects on mortality.
Early cardiovascular readmissions are frequently
caused by recurrent HF decompensation, probably as
a consequence of either incomplete decongestion
during the index hospital admission or rapid recur-
rence of congestion in the early post-discharge in-
terval (19). Accordingly, therapeutic approaches that
facilitate better management of congestion seem to
be effective in reducing readmission rates (20). Our
analysis indicates that compared with those treated
with enalapril, patients with chronic HF treated with
LCZ696 are both less likely to be initially hospitalized
for HF decompensation, and less likely to require
hospital readmission for any reason within 30 days of
hospital discharge. Because angiotensin-converting
enzyme inhibitors and angiotensin-receptor blockers
have comparable clinical beneﬁts in HF with reduced
ejection fraction, it seems likely that the improve-
ment in early post-discharge clinical outcomes is
related to the incremental beneﬁt of neprilysin inhi-
bition over renin-angiotensin system antagonism
alone, particularly with regard to HF readmissions,
which were also lower in LCZ696-treated subjects.
This impact on readmissions after HF hospitalization
should be viewed in context of the already estab-
lished 21% reduction in risk of ﬁrst HF hospitalization
compared with enalapril, and provides more granular
insight into the 23% reduction in cumulative burden
of HF hospitalization that has previously been re-
ported (7). Although the mechanisms by which
neprilysin inhibition may help to facilitate read-
mission reduction early after HF hospitalization
remain unclear, these data further support the po-
tential beneﬁts of this approach on slowing the clin-
ical progression of patients surviving with HF.
STUDY LIMITATIONS. This analysis must be viewed
in the context of its limitations. First, this was not a
pre-speciﬁed analysis of the PARADIGM-HF study,
and patients were not randomized to treatment with
LCZ696 or enalapril at the time of index hospitaliza-
tion. Accordingly, the apparent differences in read-
mission rates noted in this analysis could be
attributed to differences in the patients who were
hospitalized for HF in the 2 treatment groups. How-
ever, we noted no signiﬁcant treatment-related dif-
ferences in baseline characteristics and indices of HF
severity among patients discharged following HF
hospitalization (Table 1). To more closely mimic the
approach used in the United States to apply ﬁnancial
penalties for early readmissions, our primary analysisfocused on readmissions following investigator-
reported HF hospitalizations, which are vulnerable
to misclassiﬁcation; nonetheless, the readmission
reductions seen with LCZ696 were consistent in
sensitivity analyses limited to HF hospitalizations
conﬁrmed by a blinded CEC. Because the risk for
readmission persists well beyond 30 days, the focus
on early readmissions here may seem shortsighted;
however, payers in the United States and Australia
have emphasized the rate of 30-day readmissions af-
ter HF hospitalization as a key quality metric and U.S.
hospitals are increasingly focused on this time point
because of the ﬁnancial penalties for excessive
readmissions imposed by Centers for Medicare &
Medicaid Services. Consistency in the results for
readmission at 60 days and in analyses restricted to
Medicare-eligible patients suggests that the beneﬁts
of LCZ696 over enalapril are clinically relevant and
not simply related to the play of chance.
CONCLUSIONS
Reducing early readmissions after HF hospitalization
represents an opportunity to simultaneously improve
patient outcomes and reduce the ﬁscal burden of HF
management for hospitals and payers. These data
highlighting fewer all-cause and heart-failure read-
missions at 30 days during treatment with LCZ696
relative to enalapril provide additional rationale for
use of sacubitril/valsartan in preference to enalapril
in patients with chronic, symptomatic HF and
reduced ejection fraction.
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